Adicet Bio’s Q1 2026 update reveals operational momentum marked by doubling enrollment in its prula-cel Phase 1 trials for autoimmune diseases and FDA agreement on outpatient dosing protocols. The company targets a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer within H1 2026, signaling pipeline maturation. With cash and equivalents of $36.2 million and a current ratio of 7.65, Adicet maintains robust short-term financial resources to support clinical development despite continued operating losses typical of early-stage biopharma [S2][S3][S6][F1].